Our Vectorology™ platform produces novel vector conjugates that carry more and reach further, dramatically expanding the possibilities in drug development.
Our Vectorology™ platform has the potential to deliver nearly any cargo to any tissue in the body, creating an entirely new field for targeted medicines.
Chris McNulty, Ring CEO
What we do
Pioneering a new class of targeted medicines that deliver more
Ring is taking a novel approach to engineering vector-based therapies that can safely and effectively deliver therapies to target cells and tissues.
Science
Harnessing the untapped power of the human commensal virome
Through millions of years of harmonious evolution, commensal viruses found in humans developed several unique and differentiating features that can be harnessed into the ideal vector therapeutic: they are extraordinarily diverse, they are ubiquitous not only within the human population but within all tissues in the body, and they naturally evade the immune system.
Ring is harnessing these intrinsic traits to develop vector conjugate therapies capable of tissue and cellular tropism, payload versatility, potency and redosability.
Platform
End-to-end drug design engine with unprecedented modularity and applications
Our platform unites our powerful vector-based technology for delivering diverse payloads with a highly scalable and modular manufacturing platform, opening a new frontier for targeted medicines with larger therapeutic windows, reduced resistance potential, simplified production and even new mechanisms and functionalities.
Careers
We push boundaries of what’s possible
Through building a team comprising the leading experts and pioneers, we are working together to bring the next generation of therapies to patients with significant need.